Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Moore, Nathan F., Azarova, Anna M., Bhatnagar, Namrata, Ross, Kenneth N., Drake, Lauren E., Frumm, Stacey, Liu, Qinsong S., Christie, Amanda L., Sanda, Takaomi, Chesler, Louis, Kung, Andrew L., Gray, Nathanael S., Stegmaier, Kimberly, George, Rani E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226718/
https://ncbi.nlm.nih.gov/pubmed/25228590
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky